Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS2 | P35228 | 2/20 | 0.39 |
| ▸ | NOS3 | P29474 | 1/20 | 0.39 |
| ▸ | NOS1 | P29475 | 1/20 | 0.39 |
| ▸ | TLR8 | Q9NR97 | 11/20 | 0.38 |
| ▸ | TLR7 | Q9NYK1 | 4/20 | 0.37 |
| ▸ | DHFR | P00374 | 1/20 | 0.36 |
| ▸ | EGFR | P00533 | 1/20 | 0.36 |
| ▸ | CYSLTR2 | Q9NS75 | 1/20 | 0.34 |
| ▸ | CYSLTR1 | Q9Y271 | 1/20 | 0.34 |
| ▸ | ADA | P00813 | 1/20 | 0.33 |
| ▸ | IDO1 | P14902 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11401188 | 0.97 | NOS2 (0.41) | NOS2NOS3NOS1TLR8TLR7 | |
| SCHEMBL21142402 | 0.94 | ADA (0.39) | NOS2NOS3NOS1TLR8TLR7 | |
| SCHEMBL19779582 | 0.92 | ADA (0.40) | NOS2NOS3NOS1TLR8TLR7 | |
| SCHEMBL20621502 | 0.90 | ADA (0.40) | NOS2NOS3NOS1TLR8TLR7 | |
| SCHEMBL21883583 | 0.90 | ADA (0.40) | NOS2NOS3NOS1TLR8TLR7 | |
| SCHEMBL29814823 | 0.90 | NOS2 (0.39) | NOS2NOS3NOS1TLR8TLR7 | |
| SCHEMBL29814520 | 0.84 | ADA (0.39) | NOS2NOS3NOS1TLR8TLR7 | |
| SCHEMBL26169752 | 0.82 | CYSLTR2 (0.35) | TLR8TLR7CYSLTR2CYSLTR1IDO1 | |
| SCHEMBL19779990 | 0.82 | NOS2 (0.40) | NOS2NOS3NOS1TLR8TLR7 | |
| SCHEMBL21884025 | 0.81 | CYSLTR2 (0.37) | TLR8TLR7CYSLTR2CYSLTR1IDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210171492-A1 | SOMATOSTATIN MODULATORS AND USES THEREOF | Crinetics Pharmaceuticals, Inc. | 2021-06-10 | — | — | US | disclosed |
| US-10597377-B2 | Somatostatin modulators and uses thereof | Crinetics Pharmaceuticals, Inc. (US) | 2020-03-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10597377-B2 | Somatostatin modulators and uses thereof | SSTR5, SSTR2, SSTR4 | NOS2 1227/4885NOS3 887/4885NOS1 1317/4885 |
| US-20210171492-A1 | SOMATOSTATIN MODULATORS AND USES THEREOF | SSTR5, SSTR2, SSTR4 | NOS2 1227/4885NOS3 887/4885NOS1 1317/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.